Archives of Virology

, Volume 161, Issue 5, pp 1183–1187 | Cite as

No evidence of persistent parvovirus B19 viremia among Iranian patients with HIV after a 1-year follow-up

  • Arezoo Aghakhani
  • Minoo Mohraz
  • Kayhan Azadmanesh
  • Saeedeh Moayedi-Nia
  • Monireh Kazemimanesh
  • Setareh Mamishi
  • Mohammad Banifazl
  • Amitis RamezaniEmail author
Original Article


Recent studies have demonstrated that, in common with other latent viruses, parvovirus B19 infection can be controlled by the host immune response but may persist in some places such as the bone marrow. Persistent B19 infection has been found in both immunocompetent and immunocompromised individuals, such as patients infected with human immunodeficiency virus (HIV). However, there is limited data regarding long-term B19 viremia in HIV patients. In this study, we investigated virological and hematological findings, and also the clinical outcome, of seven cases of HIV/B19 coinfection (confirmed by PCR) after one year. These cases were provided from a previous study on patients with HIV infection that found B19 DNA in 13 cases. Seven of these 13 patients were available after 1 year, and we retested them for B19 viremia and B19-specific antibodies. B19 IgG was tested by ELISA, and B19 DNA was assessed by nested PCR. Anemia was not observed in these cases. All subjects had cleared viremia, but B19 IgG seroconversion occurred in two cases. No significant changes in CD4 and hemoglobin occurred. The results of this study indicate that B19 infection in HIV patients is a subtle infection and that B19 viremia is not a long-term event.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Patient Hematological Finding Human Immunodeficiency Virus Case 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors are grateful to Iranian Society for Support of Patients with Infectious Disease for financial support of this study.


  1. 1.
    Corcoran A, Doyle S (2004) Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 53:459–475CrossRefPubMedGoogle Scholar
  2. 2.
    Intalapaporn P, Poovorawan Y, Suankratay C (2006) Immune reconstitution syndrome associated with parvovirus B19-induced pure red cell aplasia during highly active antiretroviral therapy. J Infect 53(2):e79–e82CrossRefPubMedGoogle Scholar
  3. 3.
    Henriques I, Monteiro F, Meireles E, Cruz A, Tavares G, Ferreira M, Araújo F (2005) Prevalence of parvovirus B19 and hepatitis A virus in Portuguese blood donors. Transfus Apher Sci 33(3):305–309CrossRefPubMedGoogle Scholar
  4. 4.
    Heegaard ED, Brown KE (2002) Human parvovirus B19. Clin Microbiol Rev 15(3):485–505CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wildig J, Cossart Y, Peshu N, Gicheru N, Tuju J, Williams TN, Newton CR (2010) Parvovirus B19 infection and severe anemia in Kenyan children: a retrospective case control study. BMC Infect Dis 10:88CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Buyukkose M, Kozanoglu E, Basaran S, Bayramoglu O, Yarkin F (2009) Seroprevalence of parvovirus B19 in fibromyalgia syndrome. Clin Rheumatol 28:305–309CrossRefPubMedGoogle Scholar
  7. 7.
    Bremner JA, Cohen BJ (1994) Parvovirus B19 as a cause of anemia in human immunodeficiency virus-infected patients. J Infect Dis 169:938–940CrossRefPubMedGoogle Scholar
  8. 8.
    Chernak E, Dubin G, Henry D, Naides SJ, Hodinka RL, MacGregor RR, Friedman HM (1995) Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis 20:170e3CrossRefGoogle Scholar
  9. 9.
    Anderson L, Tsou C, Parker R, Chorba T, Wulff H, Tattersall P, Mortimer P (1986) Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 24(4):522–526PubMedPubMedCentralGoogle Scholar
  10. 10.
    Erdman DD, Usher MJ, Tsou C, Caul EO, Gary GW, Kajigaya S, Young NS, Anderson LJ (1991) Human parvovirus B19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum. J Med Virol 35(2):110–115CrossRefPubMedGoogle Scholar
  11. 11.
    Cassinotti P, Weitz M, Siegl G (1993) Human parvovirus B19 infections: routine diagnosis by a new nested polymerase chain reaction assay. J Med Virol 40(3):228–234CrossRefPubMedGoogle Scholar
  12. 12.
    Lefrere JJ, Servant-Delmas A, Candotti D, Mariotti M, Thomas I, Brossard Y, Lefrère F, Girot R, Allain JP, Laperche S (2005) Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 106(8):2890–2895CrossRefPubMedGoogle Scholar
  13. 13.
    Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS (1987) Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 317:287e94CrossRefGoogle Scholar
  14. 14.
    Lehmann HW, von Landenberg P, Modrow S (2003) Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2:218e23CrossRefGoogle Scholar
  15. 15.
    Pont J, Puchhammer-Stockl E, Chott A, Popow-Kraupp T, Kienzer H, Postner G, Honetz N (1992) Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol 80:160e5CrossRefGoogle Scholar
  16. 16.
    Azadmanesh K, Mohraz M, Kazemimanesh M, Aghakhani A, Foroughi M, Banifazl M, Eslamifar A, Ramezani A (2015) Frequency and genotype of human parvovirus B19 among Iranian patients infected with HIV. J Med Virol 87(7):1124–1129CrossRefPubMedGoogle Scholar
  17. 17.
    Kerr JR, Barah F, Mattey DL, Laing I, Hopkins SJ, Hutchinson IV, Tyrrell DA (2001) Circulating tumour necrosis factor-α and interferon-γ are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 82(12):3011–3019CrossRefPubMedGoogle Scholar
  18. 18.
    Toan NL, Duechting A, Kremsner PG, le Song H, Ebinger M, Aberle S, Binh VQ, Duy DN, Torresi J, Kandolf R, Bock CT (2006) Phylogenetic analysis of human parvovirus B19, indicating two subgroups of genotype 1 in Vietnamese patients. J Gen Virol 87(10):2941–2949CrossRefPubMedGoogle Scholar
  19. 19.
    Adamson-Small LA, Ignatovich IV, Laemmerhirt MG, Hobbs JA (2014) Persistent parvovirus B19 infection in non-erythroid tissues: possible role in the inflammatory and disease process. Virus Res 190:8–16CrossRefPubMedGoogle Scholar
  20. 20.
    Kerr JR (2000) Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 59(9):672–683CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lindblom A, Isa A, Norbeck A, Wolf S, Johansson B, Broliden K, Tolfvenstam T (2005) Slow clearance of human parvovirus B19 viremia following acute infection. Clin Infect Dis 41:1201–1203CrossRefPubMedGoogle Scholar
  22. 22.
    He M, Zhu J, Yin H, Ke L, Gao L, Pan Z, Yang X, Li W (2012) Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China. Blood Transfus 10(4):502–514PubMedPubMedCentralGoogle Scholar
  23. 23.
    van Elsacker-Niele AMW, Kroon FP, van der Ende ME, Salimans MM, Spaan WJ, Kroes AC (1996) Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. Clin Infect Dis 23:1255–1260CrossRefGoogle Scholar
  24. 24.
    Mylonakis E, Dickinson BP, Mileno MD, Flanigan T, Schiffman FJ, Mega A, Rich JD (1999) Persistent parvovirus related anaemia of seven years duration in a HIV infected patient: complete remission of highly active antiretroviral therapy. Am J Hem 60:164–166CrossRefGoogle Scholar
  25. 25.
    Ware AJ, Moore T (2001) Resolution of chronic parvovirus B19-induced anaemia by use of highly active antiretroviral therapy in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 32:122–123CrossRefGoogle Scholar
  26. 26.
    von Poblotzki A, Gigler A, Lang B, Wolf H, Modrow S (1995) Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol 76(3):519–527CrossRefGoogle Scholar
  27. 27.
    Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM, Young NS (1989) Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 84:1114–1123CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Pereira RF, Garcia Rde C, de Azevedo KM, Setúbal S, de Siqueira MA, de Oliveira SA (2014) Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients. Mem Inst Oswaldo Cruz 109(2):168–173PubMedPubMedCentralGoogle Scholar
  29. 29.
    Kerr JR, Curran MD, Moore JE, Murphy PG (1995) Parvovirus B19 infection; persistence and genetic variation. Scand J Infect Dis 27:551–557CrossRefPubMedGoogle Scholar
  30. 30.
    Frickhofen N, Young NS (1990) Polymerase chain reaction for detection of parvovirus B19 in immunodeficient patients with anaemia. Behring Inst Mitt 85:46–54PubMedGoogle Scholar
  31. 31.
    Gyllensten K, Sonnerborg A, Jorup-Ronstrom C, Halvarsson M, Yun Z (1994) Parvovirus B19 infection in HIV-1 infected patients with anemia. Infection 22:356–358CrossRefPubMedGoogle Scholar
  32. 32.
    Hitzler WE, Runkel S (2002) Prevalence of human parvovirus B19 in blood donors as determined by a haemagglutination assay and verified by the polymerase chain reaction. Vox Sang 82:18–23CrossRefPubMedGoogle Scholar
  33. 33.
    Hemauer A, von Poblotzki A, Gigler A, Cassinotti P, Siegl G, Wolf H, Modrow S (1996) Sequence variability among different parvovirus B19 isolates. J Gen Virol 77(8):1781–1785CrossRefPubMedGoogle Scholar
  34. 34.
    Kerr J, Curran M (1996) Applications of polymerase chain reaction-single stranded conformational polymorphism to microbiology. Clin Mol Pathol 49(6):M315–M320CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Diss TC, Pan LX, Du MQ, Peng HZ, Kerr JR (1999) Parvovirus B19 is associated with benign testes as well as testicular germ cell tumours. Mol Pathol 52(6):349–352CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Gray A, Guillou L, Zufferey J, Rey F, Kurt AM, Jichlinski P, Leisinger HJ, Benhattar J (1998) Persistence of parvovirus B19 DNA in testis of patients with testicular germ cell tumours. J Gen Virol 79(3):573–579CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Arezoo Aghakhani
    • 1
  • Minoo Mohraz
    • 2
  • Kayhan Azadmanesh
    • 3
  • Saeedeh Moayedi-Nia
    • 2
  • Monireh Kazemimanesh
    • 3
  • Setareh Mamishi
    • 4
  • Mohammad Banifazl
    • 5
  • Amitis Ramezani
    • 1
    Email author
  1. 1.Clinical Research DepartmentPasteur Institute of IranTehranIran
  2. 2.Iranian Research Center for HIV/AIDSTehranIran
  3. 3.Virology DepartmentPasteur Institute of IranTehranIran
  4. 4.Pediatric Infectious Disease Research CenterTehran University of Medical SciencesTehranIran
  5. 5.Iranian Society for Support of Patients with Infectious DiseaseTehranIran

Personalised recommendations